Neon Therapeutics Obtains $55,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8a859408-8e80-436b-a73f-a924c95f3631 - Date
10/2/2015 - Company Name
Neon Therapeutics - Mailing Address
215 First Street Cambridge, MA 02142 USA - Company Description
We have assembled a team of world experts in cancer immunotherapy to develop therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. Our programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need. - Website
http://www.neontherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$55,000,000 - Transaction Round
Series A - Proceeds Purposes
The contributions from world-leading experts in core scientific advances in neoantigen biology have paved the way for the founding of Neon Therapeutics, and the company plans to work closely with them moving forward to bring new therapies to patients. - M&A Terms
- Venture Investor
Third Rock Ventures - Venture Investor
Access Industries - Venture Investor
Clal Biotechnology Industries
